Cynata Therapeutics Limited (CYP.AX)
AUD 0.2
(2.63%)
AUD 0.2
(2.63%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 11.12 Million AUD | -31.6% |
| 2023 | 16.26 Million AUD | 145.65% |
| 2022 | 6.62 Million AUD | -24.77% |
| 2021 | 8.8 Million AUD | -13.99% |
| 2020 | 10.23 Million AUD | 4.61% |
| 2019 | 9.78 Million AUD | 67.17% |
| 2018 | 5.85 Million AUD | -3.33% |
| 2017 | 6.05 Million AUD | 2.57% |
| 2016 | 5.9 Million AUD | 38.48% |
| 2015 | 4.26 Million AUD | 35.38% |
| 2014 | 3.14 Million AUD | 260.35% |
| 2013 | 873.43 Thousand AUD | -36.85% |
| 2012 | 1.38 Million AUD | -45.29% |
| 2011 | 2.52 Million AUD | 32.64% |
| 2010 | 1.9 Million AUD | 34.26% |
| 2009 | 1.41 Million AUD | -11.67% |
| 2008 | 1.6 Million AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 6.94 Million AUD | 0.0% |
| 2024 FY | 12.26 Million AUD | -24.58% |
| 2024 Q4 | 12.85 Million AUD | 0.0% |
| 2023 Q2 | 6.83 Million AUD | 0.0% |
| 2023 Q4 | 9.17 Million AUD | 0.0% |
| 2023 FY | 16.26 Million AUD | 145.65% |
| 2022 Q2 | 1.02 Million AUD | 0.0% |
| 2022 Q4 | 5.03 Million AUD | 0.0% |
| 2022 FY | 6.62 Million AUD | -24.77% |
| 2021 Q2 | 4.81 Million AUD | 0.0% |
| 2021 FY | 8.8 Million AUD | -13.99% |
| 2021 Q4 | 4.28 Million AUD | 0.0% |
| 2020 Q2 | 6.93 Million AUD | 0.0% |
| 2020 FY | 10.23 Million AUD | 4.61% |
| 2020 Q4 | 3.57 Million AUD | 0.0% |
| 2019 Q2 | 4.41 Million AUD | 0.0% |
| 2019 FY | 9.78 Million AUD | 67.17% |
| 2019 Q4 | 5.48 Million AUD | 0.0% |
| 2018 Q4 | 2.81 Million AUD | 0.0% |
| 2018 FY | 5.85 Million AUD | -3.33% |
| 2018 Q2 | 3.26 Million AUD | 0.0% |
| 2017 Q4 | 3.6 Million AUD | 0.0% |
| 2017 Q2 | 2.79 Million AUD | 0.0% |
| 2017 FY | 6.05 Million AUD | 2.57% |
| 2016 Q2 | 3.48 Million AUD | 0.0% |
| 2016 Q4 | 2.7 Million AUD | 0.0% |
| 2016 FY | 5.9 Million AUD | 38.48% |
| 2015 FY | 4.26 Million AUD | 35.38% |
| 2015 Q4 | 2.62 Million AUD | 0.0% |
| 2015 Q2 | 1.46 Million AUD | 0.0% |
| 2014 FY | 3.14 Million AUD | 260.35% |
| 2014 Q4 | 1.37 Million AUD | 0.0% |
| 2014 Q2 | 1.77 Million AUD | 0.0% |
| 2013 Q3 | 44.06 Thousand AUD | -89.64% |
| 2013 Q2 | 425.22 Thousand AUD | 2685.28% |
| 2013 Q1 | 15.26 Thousand AUD | 0.0% |
| 2013 FY | 873.43 Thousand AUD | -36.85% |
| 2013 Q4 | 551.82 Thousand AUD | 1152.41% |
| 2012 Q4 | - AUD | -100.0% |
| 2012 Q2 | 15.26 Thousand AUD | 38.45% |
| 2012 Q1 | 11.02 Thousand AUD | 0.0% |
| 2012 FY | 1.38 Million AUD | -45.29% |
| 2012 Q3 | 15.26 Thousand AUD | 0.0% |
| 2011 Q4 | - AUD | -100.0% |
| 2011 Q3 | 11.02 Thousand AUD | 0.0% |
| 2011 Q2 | 11.02 Thousand AUD | -34.11% |
| 2011 Q1 | 16.73 Thousand AUD | 0.0% |
| 2011 FY | 2.52 Million AUD | 32.64% |
| 2010 Q3 | 16.73 Thousand AUD | 0.0% |
| 2010 Q2 | 16.73 Thousand AUD | -91.37% |
| 2010 Q4 | - AUD | -100.0% |
| 2010 Q1 | 193.87 Thousand AUD | 0.0% |
| 2010 FY | 1.9 Million AUD | 34.26% |
| 2009 Q2 | 193.87 Thousand AUD | -22.4% |
| 2009 FY | 1.41 Million AUD | -11.67% |
| 2009 Q3 | 193.87 Thousand AUD | 0.0% |
| 2009 Q1 | 249.82 Thousand AUD | 0.0% |
| 2009 Q4 | - AUD | -100.0% |
| 2008 Q4 | - AUD | -100.0% |
| 2008 Q2 | 249.82 Thousand AUD | 0.0% |
| 2008 FY | 1.6 Million AUD | 0.0% |
| 2008 Q3 | 249.82 Thousand AUD | 0.0% |
| 2008 Q1 | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2007 Q2 | - AUD | 0.0% |
| 2007 Q3 | - AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AdAlta Limited | 6.76 Million AUD | -64.319% |
| Acrux Limited | 8.55 Million AUD | -30.1% |
| Actinogen Medical Limited | 22.77 Million AUD | 51.149% |
| AnteoTech Limited | 12.18 Million AUD | 8.726% |
| Argenica Therapeutics Limited | 8.26 Million AUD | -34.519% |
| Arovella Therapeutics Limited | 10.78 Million AUD | -3.137% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -1466.221% |
| Alterity Therapeutics Limited | 23.4 Million AUD | 52.477% |
| Amplia Therapeutics Limited | 8.43 Million AUD | -31.863% |
| Avecho Biotechnology Limited | 4.54 Million AUD | -144.722% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -302.88% |
| Biome Australia Limited | 7.91 Million AUD | -40.605% |
| Biotron Limited | 5.11 Million AUD | -117.654% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -1748.321% |
| BTC Health Limited | -1.03 Million AUD | 1170.678% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | 43.728% |
| CSL Limited | 7.56 Billion AUD | 99.853% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 80.245% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 64.458% |
| Dimerix Limited | 25.64 Million AUD | 56.622% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 71.892% |
| Hexima Limited | 1 Million AUD | -1002.708% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | -169.639% |
| Immuron Limited | 9.13 Million AUD | -21.73% |
| Immutep Limited | 42.87 Million AUD | 74.056% |
| Imugene Limited | 135.09 Million AUD | 91.766% |
| Invex Therapeutics Ltd | 3.34 Million AUD | -232.455% |
| Memphasys Limited | 3.67 Million AUD | -202.404% |
| Nanollose Limited | 12.5 Thousand AUD | -88881.409% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | 65.98% |
| Noxopharm Limited | 7 Million AUD | -58.904% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -466.021% |
| Nyrada Inc. | 4.55 Million AUD | -144.197% |
| Orthocell Limited | 15.36 Million AUD | 27.626% |
| PharmAust Limited | 6.65 Million AUD | -67.096% |
| Patrys Limited | 4.93 Million AUD | -125.479% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 82.914% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -1146.837% |
| Prescient Therapeutics Limited | 10.89 Million AUD | -2.062% |
| PYC Therapeutics Limited | 60.91 Million AUD | 81.74% |
| Race Oncology Limited | 14.77 Million AUD | 24.691% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -3617.421% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | 48.703% |
| Starpharma Holdings Limited | 22.81 Million AUD | 51.247% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 95.869% |
| Tissue Repair Ltd | 6.66 Million AUD | -66.85% |
| Zelira Therapeutics Limited | 5.94 Million AUD | -86.997% |